Clinical Efficacy of Modified Gualou Xiebai Banxia Decoction in the Treatment of Stable Angina Pectoris with Internal Resistance of Phlegm and Turbidity and Its Effect on Gut Microbiota
- VernacularTitle:栝蒌薤白半夏汤加减治疗痰浊内阻型稳定型心绞痛的临床疗效及对肠道菌群的影响
- Author:
Hengsheng WANG
1
,
2
;
Yongjie FAN
;
Yuan LIU
;
Ruoya LIU
;
Xiawei WEI
;
Ying LIU
;
Yaoping TANG
Author Information
- Keywords: Modified Gualou Xiebai Banxia Decoction; Stable angina pectoris; Phlegm-turbid internal obstruction syndrome; Clinical efficacy; Gut microbiota
- From: World Science and Technology-Modernization of Traditional Chinese Medicine 2023;25(11):3626-3636
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the clinical curative effect of Modified Gualou Xiebai Banxia Decoction in the treatment of stable angina pectoris(SAP)with internal resistance of phlegm and turbidity and its effect on gut microbiota.Methods The clinical data of 72 cases of SAP patients with phlegm turbidity and internal resistance type in our hospital were selected for prospective study,sorted according to the order of admission,and divided into control group and observer by random number table method,with 36 cases in each group.The control group was given standardized western medicine treatment,and the observation group was given the addition of Modified Gualou Xiebai Banxia Decoction on the basis of the control group.The clinical efficacy and gut microbiota composition of the two groups of patients were compared.Results After treatment,the clinical efficacy of the observation group was better than that of the control group(P<0.05);there was no significant difference in the ECG efficacy between the two groups(P>0.05).Based on 16S rDNA technology,at the phylum and genus levels,there was no difference in the abundance of Bacteroidota,Bacteroides and Faecalibacterium(P>0.05).After treatment,the abundance of Bacteroidota in the observation group increased more significantly than that in the control group(P<0.05).Conclusion Modified Gualou Xiebai Banxia Decoction can effectively improve the clinical efficacy of SAP patients with phlegm-turbid internal resistance by regulating gut microbiota,which provides new inspiration for the further development of Gualou Xiebai Banxia Decoction.
